Meeting
2017 Gastrointestinal Cancers Symposium
Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).
Authors
Francesco Sclafani
The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
Francesco Sclafani , Gina Brown , David Cunningham , Sheela Rao , Paris P Tekkis , Diana M. Tait , Federica Morano , Chiara Baratelli , Eleftheria Kalaitzaki , Shahnawaz Rasheed , David J. Watkins , Naureen Starling , Andrew Wotherspoon , Ian Chau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 709)
DOI
10.1200/JCO.2017.35.4_suppl.709
Abstract #
709
Poster Bd #
J19
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Comparison of two different neoadjuvant chemoradiatiotherapy regimens for locally advanced rectal cancer: Results of a phase II, multicenter, randomized trial.
First Author: Ji Zhu
Poster
2016 ASCO Annual Meeting
Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC).
First Author: Gianluca Masi
Poster
2023 ASCO Annual Meeting
Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).
First Author: Zhenyu Lin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe